Fresenius Medical Care of North America Announces Acquisition of National Vascular Care

Fresenius Medical Care, the world’s largest provider of dialysis services and products, today announced that its subsidiary, U.S. Vascular Access Holdings, LLC has completed the acquisition of National Vascular Care Inc. Based in Rosemont, Pennsylvania, National Vascular Care is a premier provider of vascular services that works in partnership with leading vascular surgeons, nephrologists, interventional radiologists and cardiologists throughout the United States to develop, own and manage specialty outpatient surgery centers dedicated to improving the delivery of vascular care in the U.S.

The acquisition unites two market leaders that are uniquely positioned to provide physician practices with the most comprehensive set of solutions available to effectively and economically manage vascular access centers. In turn, this enables physicians to focus on clinical excellence by reducing hospital admissions related to vascular access-related complications and improving patient outcomes. The combined companies will operate under the name Fresenius Vascular Care and provide services to twelve vascular access centers and more than fifteen physician practices. Ronald Rodgers, Co-Founder, CEO and Chairman of National Vascular Care will serve as President of Fresenius Vascular Care.

"As one of the largest and most successful operators of vascular access surgery centers in the U.S., National Vascular Care has a demonstrated track record of operational and clinical excellence. We are delighted to have the opportunity to partner with Ron Rodgers and his team, and expect that the synergy of our new organization will position our company to contribute to improved patient outcomes and reduced costs to healthcare insurers,” said William Valle, Senior Vice President of Fresenius Medical Care. "We believe that the system’s demand for efficiency will continue driving the shift in these types of procedures from hospital settings to outpatient surgery centers, delivering the corresponding benefits of ease of use for physicians combined with a lower overall cost for payors. We believe that the model of partnering with leading physicians to provide superior patient outcomes will allow Fresenius Vascular Care to grow at an attractive rate. This is a significant milestone in our effort to expand our services to more physicians and access centers across the country."

"I am excited for the opportunity to join the Fresenius Medical Care team and continue the quest to provide dialysis patients in the United States with efficient access to quality vascular care. National Vascular Care was built on a set of core values – starting with quality and efficient care of patients – that we will continue with the new venture. The NVC team and I are looking forward to working with the Fresenius Medical Care clinical network and physicians to create centers of excellence for vascular care,” said Rodgers. "The efficient and proactive treatment of the vasculature of dialysis patients is critical to the efforts to reduce the cost burden on the Medicare program. We will partner with leading physicians to create centers within the Fresenius Medical Care footprint in the United States that ultimately provides nephrologists the opportunity to focus on the total continuum of care of patients.”

About Fresenius Medical Care

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,770,000 individuals worldwide. Through its network of 2,509 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 192,804 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.